Macro trends in pharmaceutical innovation

Nature Reviews Drug Discovery

Volumn 4, Issue 1, 2005, Pages 78-84

  Cohen, Fredric J ^a  

^a Crownstone   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG; PACLITAXEL; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ACCURACY; ARTICLE; COMMERCIAL PHENOMENA; COMPETITION; DRUG APPROVAL; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HUMAN; LAW; MOTIVATION; NON PROFIT ORGANIZATION; PATENT; PATIENT CARE; PRIORITY JOURNAL; PROFIT; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; WELFARE;

CLINICAL TRIALS; DRUG INDUSTRY; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); ORGANIZATIONAL INNOVATION; PHARMACEUTICAL PREPARATIONS; TECHNOLOGY TRANSFER; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 12144268237     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1610     Document Type: Article

References (29)

1. Scherer, F. M. The link between gross profitability and pharmaceutical R&D spending. An analysis that answers the question: what does the pharmaceutical industry really do with its profits? Health Affairs 20, 216-220 (2001).
2. US Congress, Office of Technology Assessment. Innovation and Commercialization of Emerging Technology OTA-BP-ITC-165 (Washington DC, US Government Printing Office, 1995).
3. National Research Council. Prospectus for national knowledge assessment. Committee on Knowledge Assessment Office of International Affairs (Washington DC, National Academy Press, 1996).
4. Booth, B. L. & Zemmel, R. W. The search for blockbuster drugs: efficacy isn't everything. The McKinsey Quart. 4 (2004).
5. Wertheimer, A., Levy, R. & O'Connor, T. Too many drugs? The clinical and economic value of incremental innovations'. Investing in health: the social and economic benefits of health care innovation 14, 77-118 (2001).
6. Roberts, P. W. Product innovation, product-market competition and persistent profitability in the U. S. pharmaceutical industry. Strategic Manag. J. 20, 655-670 (1999).
7. Grabowski, H. & Vernon, J. in Competitive Strategies in the Pharmaceutical Industry (ed. Helms, R.) 194-207 (Washington DC, AEI, 1996).
8. Ben-Asher, D. In need of treatment? Merger control, pharmaceutical innovation & consumer welfare. Discussion Paper No. 270 (Harvard Law School, Boston, 1999).
9. Congress of the United States Congressional Budget Office. How Increased Competition from Generic Drugs has Affected Prices and Returns in the Pharmaceutical Industry (Washington DC, US Government Printing Office, 1998).
10. Federal Trade Commission. To Promote Innovation: the Proper Balance of Competition and Patent Law and Policy [online], (2003).
11. Grabowski, H. G. Patents and new product development in the pharmaceutical and biotechnology industries. Georgetown Public Policy Rev. 8, 87-104 (2003).
12. US Congress, Office of Technology Assessment. Pharmaceutical R&D: Costs, Risks and Rewards OTA-H-522 (Washington DC, US Government Printing Office, 1993).
13. Pharmaceutical Research and Manufacturers of America. Industry Profile 2003 [online], (2003).
14. Grabowski, H., Vernon, J. & DiMasi, J. Returns on R&D for 1990s new drug introductions. Pharmacoeconomics 20, 11-29 (2002).
15. US Congress, Office of Technology Assessment. Patent Term Extension and the Pharmaceutical Industry (Washington DC, US Government Printing Office, 1981).
16. Pharmaceutical Research and Manufacturers of America. Delivering on the Promise of Pharmaceutical Innovation: the Need Maintain Strong and Predictable Intellectual Property Rights [online], (2002).
17. Van Horn, C. E. in Biotechnology Innovation Report 2004 Benchmarks (ed. Michelson A. M.) 1-33 (Washington DC, Finnegan, Henderson, Frabow, Garrett & Dunner, LLP, 2004).
18. McGahan, A. & Silverman, B. How does innovative activity change as industries mature? Intl J. Ind. Organ. 19, 1141-1160 (2001).
19. National Science Foundation. Science and Engineering Indicators 2004 Vol. 2. [online], (2004).
20. National Science Foundation. Survey of Industrial Research and Development 1953-2003 [online], (2004).
21. US Department of Labour: Bureau of Labour Statistics Occupational Employment Statistics [online],
22. Reichert, J. M. & Paquette C. Therapeutic recombinant proteins: trends in US approvals 1982 to 2002. Curr. Opin. Mol. Ther. 5, 139-147 (2003).
23. Parexel's R&D Statistical Sourcebook 2004/2005 (ed. Mathieu, M. P.) (Parexel Intl Corp., Waltham, 2004).
24. Anonymous. From pipeline to market 2004. R&D Directions 10, 19-74 (2004).
25. Patent Statistics Reports [online],
26. Pharmaceutical Research and Manufacturers of America. Industry Profile 2004 [online], (2004).
27. Department of Health and Human Services National Institutes Of Health. NIH response to the conference report request for a plan to ensure taxpayers' interests are protected [online], (2001).
28. Department of Health and Human Services National Institutes of Health report to Congress on affordability of inventions and products [online], (2004).
29. Center for Drug Evaluation and Research. Report to the Nation 2003: Improving Public Health Through Human Drugs [online], (2003).